Neurocrine(NBIX) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Neurocrine Biosciences Reports Second Quarter 2025 Financial Results Achieved Total Net Product Sales of $682 Million Representing 17% Year-Over-Year Growth INGREZZA (valbenazine) Second-Quarter 2025 Net Product Sales of $624 Million and Narrows 2025 Net Product Sales Guidance to $2.5 - $2.55 Billion ® CRENESSITY (crinecerfont) Second-Quarter 2025 Net Product Sales of $53 Million with 664 Total New Patient Enrollment Start Forms ® SAN DIEGO, July 30, 2025 – Neurocrine Biosciences, Inc. (Nasdaq: ...